“I am a patient with Primary Plasma Cell Leukemia, the rarest and most aggressive variant of Multiple Myeloma (only about 150 patients in the US). I have been taking Revlimid for 3 years now, with a Medicare co-payment of around $ 575 for a 3-week cycle. I feel strongly that the Revlimid REMS program (ditto for Thalomid and Pomalyst) has been abused in order to limit and delay generic competition because it has been next to impossible to secure reference drug needed to develop and file a ANDA.”
Share your story
The prescription drug pricing system in the U.S. is rigged against patients. We are fighting to change that.
Patients For Affordable Drugs will collect patient stories and amplify the voices of patients to make policymakers understand the heavy toll of high priced drugs.Share your story